Current studentsExisting staffContact us
 

Titanium dioxide nanoparticles as radiosensitisers: An in vitro and phantom-based study

Simple item page
dc.contributor.authorYoukhana, E.Q.
dc.contributor.authorFeltis, B.
dc.contributor.authorBlencowe, A.
dc.contributor.authorGeso, M.
dc.date.issued2017
dc.description.abstract<b>Objective:</b> Radiosensitisation caused by titanium dioxide nanoparticles (TiO<sub>2</sub>-NPs) is investigated using phantoms (PRESAGE<sup>®</sup> dosimeters) and <i>in vitro</i> using two types of cell lines, cultured human keratinocyte (HaCaT) and prostate cancer (DU145) cells. <b>Methods:</b> Anatase TiO<sub>2</sub>-NPs were synthesised, characterised and functionalised to allow dispersion in culture-medium for <i>in vitro</i> studies and halocarbons (PRESAGE<sup>®</sup> chemical compositions). PRESAGE<sup>®</sup> dosimeters were scanned with spectrophotometer to determine the radiation dose enhancement. Clonogenic and cell viability assays were employed to determine cells survival curves from which the dose enhancement levels "radiosensitisation" are deduced. <b>Results:</b> Comparable levels of radiosensitisation were observed in both phantoms and cells at kilovoltage ranges of x-ray energies (slightly higher <i>in vitro)</i>. Significant radiosensitisation (~67 %) of control was also noted in cells at megavoltage energies (commonly used in radiotherapy), compared to negligible levels detected by phantoms. This difference is attributed to biochemical effects, specifically the generation of reactive oxygen species (ROS) such as hydroxyl radicals (<sup>•</sup>OH), which are only manifested in aqueous environments of cells and are non-existent in case of phantoms. <b>Conclusions:</b> This research shows that TiO<sub>2</sub>-NPs improve the efficiency of dose delivery, which has implications for future radiotherapy treatments. Literature shows that Ti<sub>2</sub>O<sub>3</sub>-NPs can be used as imaging agents hence with these findings renders these NPs as theranostic agents.
dc.identifier.citationInternational Journal of Medical Sciences, 2017; 14(6):602-614
dc.identifier.doi10.7150/ijms.19058
dc.identifier.issn1449-1907
dc.identifier.issn1449-1907
dc.identifier.orcidBlencowe, A. [0000-0002-7630-4874]
dc.identifier.urihttps://hdl.handle.net/11541.2/128453
dc.language.isoen
dc.publisherIVYSPRING INT PUBL
dc.relation.fundingRMIT Unviersity
dc.relation.fundingUniversity of Melbourne
dc.rightsCopyright 2017 Ivyspring International Publisher. This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/)
dc.source.urihttps://doi.org/10.7150/ijms.19058
dc.subjectCell Line, Tumor
dc.subjectKeratinocytes
dc.subjectHumans
dc.subjectProstatic Neoplasms
dc.subjectTitanium
dc.subjectReactive Oxygen Species
dc.subjectRadiation Dosage
dc.subjectRadiation Tolerance
dc.subjectMale
dc.subjectMetal Nanoparticles
dc.titleTitanium dioxide nanoparticles as radiosensitisers: An in vitro and phantom-based study
dc.typeJournal article
pubs.publication-statusPublished
ror.fileinfo12149287320001831 13149287310001831 v14p0602
ror.mmsid9916149099701831

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
v14p0602.pdf
Size:
2.11 MB
Format:
Adobe Portable Document Format
Description:
Published version
Download

Collections